R
Revolution Medicines
Senior Administrative Assistant II, Commercialization
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic var... Show details
$99k-$124kAPIDataGoMedicalOperationsremote
ApplyR
Revolution Medicines
Director, Medical Science Liaison, GI (IL, IN)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic var... Show details
$236k-$259kAPIDataMarketingOperationsPlatformremote
ApplyR
Revolution Medicines
Associate Director, Commercial Regulatory Affairs
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic var... Show details
$186k-$233kAPIDataGoPlatformProductremote
ApplyR
Revolution Medicines
Executive Director, National Portfolio Field Excellence
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic var... Show details
$252k-$315kAPIDataGoMarketingOperationsremote
ApplyR
Revolution Medicines
Executive Director, Global Commercial Precision Medicine & Companion Diagnostics
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic var... Show details
$252k-$315kAPIDataPlatformProductRustremote
ApplyR
Revolution Medicines
Senior Director, Field HEOR
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic var... Show details
$259k-$285kAPIDataPlatformProductReactremote
Apply